The FDA Meeting Nobody's Talking About

Seven Peptides. Two Days. One FDA Meeting That Changes Everything.

The FDA's July 2026 calendar could reshape access to peptide therapeutics and GLP-1 medications. This clinician-ready briefing breaks down what's under review and what it means for the future of compounded therapies.

Peptides under formal FDA review (July 23–24):

• BPC-157 — soft tissue healing & gut repair

• TB-500 — tissue regeneration & inflammation

• KPV — inflammation & gut barrier support

• Semax — cognitive function & neuroprotection

• Epitalon — telomere biology & circadian regulation

• MOTS-c — metabolic & exercise capacity

• Emideltide (DSIP) — sleep & stress response

GLP-1 update on the summer docket:

• CagriSema — next-gen combination injection (cagrilintide + semaglutide) targeting multiple appetite pathways; expected to potentially outperform current GLP-1 monotherapies

Plus PDUFA decisions on Orca-T (blood cancers) and Atacicept (kidney disease), and ongoing reviews of Rusfertide and Veligrotug.